STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

His nomination to head the HHS by President-elect Donald Trump on Thursday could bring sweeping changes to the way Washington, D.C., targets health issues.

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

President-elect Donald Trump said he is tapping Robert F. Kennedy Jr., to run the Department of Health and Human Services, a ...

The nearly $2 trillion agency administers health-insurance programs for millions of Americans, approves medications and ...

One of the most remarkable aspects of the populist alliance between Robert F. Kennedy Jr. and Donald Trump is that it puts ...

After pledging to allow politician and vaccine skeptic Robert Francis Kennedy Jr. | Trump's appointment follows his ...

By big pharma standards, these were massive moves that in one fell swoop crowned Bristol-Myers the runaway leader in a ...

The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and ...

During his presidential campaign, Kennedy developed a national profile for his criticism of the Covid vaccines and childhood ...

President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr., to run the Department of Health and Human Services, a ...

The rapid progress in AI has also facilitated real-life applications within the pharmaceutical industry that may lead to ...